HALO
Halozyme Therapeutics, Inc.
Is HALO Halal?
Injectable-drug delivery technology and pharmaceutical licensing — generally permissible activity, but the current debt/assets screen fails.
What You Should Know
Halozyme's March 31, 2026 Form 10-Q reports assets of $2,672.719 million, debt of $2,144.639 million, cash of $309.749 million, available-for-sale securities of $8.873 million, receivables of $457.989 million and quarterly revenue of $376.708 million. Debt/assets is 80.24%, above examined limits; liquidity/assets is 11.92%, receivables plus cash/assets is 28.75% and investment and other income is a $1.318 million conservative upper bound. No universal prohibited-revenue numerator is disclosed.
⚠️ Concerns
- •Debt/assets is 80.24%, above examined 33% limits
- •Pharmaceutical licensing and partner end uses require qualitative review
- •Royalty concentration and acquisition-related leverage
- •Investment-income classification
- •No universal prohibited-revenue numerator is disclosed
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
2,144.639 / 2,672.719
318.622 / 2,672.719
767.738 / 2,672.719
1.318 / 376.708
- Financial
- Fails
- Overall
- Fails
Debt/assets is 80.24%, above the examined limit; liquidity/assets is 11.92% and receivables-plus-cash/assets is 28.75%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 80.24%, above the examined limit; this is not an index-membership claim.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 80.24%, above the examined limit; this is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; asset-based debt screens already fail.
Business-activity disclosure
Halozyme develops injectable-drug delivery technologies and earns royalties, product sales and collaborative-agreement revenue. Healthcare technology is generally permissible, but the filing does not provide a universal prohibited-revenue numerator for licensing and end uses.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed.
Purification
Investment and other income is disclosed as a mixed net amount; no fixed purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are USD thousands from Halozyme's March 31, 2026 Form 10-Q; this record expresses them in millions-equivalent values.
- Debt is current and non-current long-term debt of $208.743 million and $1,935.896 million; operating leases are excluded.
- Cash is $309.749 million and available-for-sale securities are $8.873 million; accounts receivable and contract assets are $457.989 million.
- Quarterly revenue is $376.708 million and investment and other income, net is $1.318 million, used as a conservative upper bound.
- Drug-delivery licensing and pharmaceutical end uses remain qualitative; no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →